Amarin Corp. plc (NASDAQ:AMRN): 10:18 EDT Amarin jumps 15%, or $1.30, to $10.21.
The shares closed at $10.52, up $1.61, or 18.07%, on the day. Its market capitalization is $1.43 billion.
Cytori Therapeutics Inc. (NASDAQ:CYTX): Cytori has received 510k clearance from the U.S. FDA for the Puregraft 850 System for body contouring using a patient’s own fat. The Puregraft 850 product line extension provides optimized and sterile processing of up to 850 mL of tissue, a significantly larger volume than the Puregraft 250, which received a 510k in January 2010. Larger tissue volumes expand the range of soft tissue procedures for which the product line may be used.
The shares closed at $3.13, up $0.3, or 10.6%, on the day. Its market capitalization is $177.14 million.
Pfizer Inc. (NYSE:PFE): Pfizer (NYSE:PFE) is not likely to accept Bayer’s (BAYRY) preliminary offer to buy Pfizer’s animal health unit, Dow Jones reports, citing Financial Times Deutschland. According to a memo Bayer CEO Marijn Dekkers sent to supervisory board members, Pfizer is more likely to take the unit public.
The shares closed at $21.94, up $0.03, or 0.14%, on the day. Its market capitalization is $165.40 billion.
Merck & Co., Inc. (NYSE:MRK): In briefing documents posted by the FDA in advance of a March 20 meeting to evaluate ridaforolimus, developed by ARIAD Pharmaceuticals (NASDAQ:ARIA) in partnership with Merck (NYSE:MRK), FDA staff asked whether the risk-benefit assessment is favorable for the use of the drug in the treatment of patients with soft tissue and bone sarcoma who have received prior chemotherapy “given the small differences in median PFS and OS between arms, the adverse event profile of ridaforolimus, and its positioning as a maintenance therapy.”
The shares closed at $38.03, down $0.03, or 0.08%, on the day. Its market capitalization is $115.76 billion.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Stella Mariz at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com